Leadership

Validation of Mild Cognitive Impairment in Parkinson Disease (MCI) Study Group

Chair: Gert J. Geurtsen (g.j.geurtsen@amc.uva.nl)

Steering Committee: Irene Litvan, Ben A. Schmand, Alexander I. Tröster, Jennifer G. Goldman and David J. Burn

Members:

USA

  • Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois (Jennifer G. Goldman)
  • Barrow Neurological Institute, Muhammad Ali Parkinson Center, Phoenix, AZ (Alexander I. Troster)
  • San Diego Medical Center and Department of Neurosciences University of California, San Diego, CA (Dr. Vincent Filoteo and Dr. Irene Litvan)
  • Departments of Psychiatry and Neurology and Parkinson’s Disease and Mental Illness Research, Philadelphia Veterans Affairs Medical Center, Philadelphia, PA (Daniel Weintraub)
  • Arizona Parkinson's Disease Consortium, Mayo Clinic Arizona, Scottsdale, AZ and Banner Sun Health Research Institute, Sun City, AZ (Charles H. Adler, Sandra Jacobson, and John Caviness)
  • Department of Neurology, University of Washington School of Medicine, Seattle, WA (Jim Leverenz and Cyrus Zabetian)
  • Department of Neurology, Hershey Medical Center (Xuemei Huang and Paul Eslinger)

Canada

  • Movement Disorders Centre and Safra Program in Parkinson’s research, Toronto Western Hospital (Dr. Connie Marras and Dr. Sarah Duff-Canning)

New Zealand

  • Van der Veer Institute for Parkinson’s disease and brain research, Christchurch (Dr. John C. Dalrymple-Alford and Dr. Tim J. Anderson)

Australia

  • Brain & Mind Research Institute, The University of Sydney (Dr. Sharon L. Naismith, Dr. Simon JG Lewis and Dr. Glenda M. Halliday)

Taiwan

  • Department of Neurology and Psychology, National Taiwan University Hospital, Taipei (Dr. R.M. Wu and Rwei-Ling Yu)

India

  • Department of Neuromedicine, Bangur Institute of Neurology, Kolkata (Dr. K.B. Bhattacharyya)

UK

  • Cambridge Center for Brain Repair, University of Cambridge (Dr. Caroline H. Williams-Gray, Dr. David P. Breen and Dr. Roger A. Barker)
  • Institute for Ageing and Health, Newcastle University (David J. Burn and Dr. Alison J. Yarnall)

The Netherlands

  • Department of Neurology, AMC and University of Amsterdam (Dr. Ben A. Schmand and Dr. Rob M.A. de Bie);
  • VU Neurology department (Ted Koene and Dr. Martin Klein)

Germany

  • Paracelsus-Elena-Klinik, Kassel, and Georg-August University Goettingen (Dr. Brit Mollenhauer and Dr. Ellen Trautmann)

Spain

  • Movement Disorders Unit, Neurology Department, Hospital and Institute of Biomedical Research Sant Pau, Barcelona (Dr. Jaime Kulisevsky and Dr. Javier Pagonabaragga)
  • Department of Neurology, Hospital Donostia, Donostia, San Sebatian and Ikerbasque, Basque Foundation for Science, Bilbao (Dr. Maria C. Rodriguez-Oroz and Dr. Carmen Gasca-Salas)
  • Department of Psychiatry and Psychobiology Clinic, Faculty of Medicin, University of Barcelona, Spain (Dr. Carme Junque and Dr. Barbara Segura)

Italy

  • Neurogenerative Disease Centre, University of Salerno (Dr. P. Barone)
  • Department of Surgery, Medical, Molecular, and Critical Area Pathology, Pisa University School fo Medicine (Dr. Marco Timpano Sportiello and Dr. Davide M. Cammisuli)

Norway

  • Parkwest study (Dr. Kenn F. Pedersen and Dr. Guido Larsen)

Goals:

1. Validation of the MDS PD-MCI criteria

  • Comparison of the two levels of criteria (abbreviated assessment versus comprehensive assessment ) in their ability to detect PD-MCI and predict conversion to dementia
  • Applicability of the criteria

2. Definition of best cut-off score

  • To discriminate patient with and without PD-MCI
  • To predict conversion to dementia

3. Generating epidemiologic data by

  • Defining the prevalence of PD-MCI
  • Comparing the prevalence across different sites/cohort types
  • Defining the prevalence of the different subtypes of PD-MCI.

The 23 international sites have PD cohorts that are being pooled. These cohorts include ≥ 5,500 PD patients and ≥ 1,700 controls to validate level I in 4,000 patients whom 89% participate in longitudinal studies and ≥ 1,600 patients to validate level II. Just over 1,200 (75%) of those level II patients are followed longitudinally.  Two PhD students started the pooling in October 2013 and the planned duration of the pooling and validation project is two years. Sites with longitudinal data on level II patients (N > 75) can still join the study group. An overview of the research plans is accepted for publication in the Journal of Parkinson's Disease.

Grants:

Michael J. Fox Foundation (Dr. Lona Vincent and Dr. Jamie Eberling)
Parkinson Vereniging (Dutch Parkinson Association)